ProfileGDS5678 / 1426168_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 49% 48% 54% 95% 46% 62% 48% 57% 54% 46% 47% 53% 47% 47% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2117449
GSM967853U87-EV human glioblastoma xenograft - Control 23.121548
GSM967854U87-EV human glioblastoma xenograft - Control 33.3314454
GSM967855U87-EV human glioblastoma xenograft - Control 48.784495
GSM967856U87-EV human glioblastoma xenograft - Control 53.0330146
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.7822762
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.1956148
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4546257
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3141254
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0615146
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.1048347
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2553353
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.1221147
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0995247